WithdrawnPhase 1/2

Platelet Rich Plasma Uterine Infusion

Stopped: Study deferred/stopped by initiator before any study recruitment was initiated.

United States0Started 2023-02-16

Plain-language summary

Platelet Rich Plasma (PRP), a rich source of important growth factors, has been shown to significantly affect the body's ability to heal and regenerate tissues. It is an affordable, accessible treatment with little risk of side effects that is being utilized in many areas of regenerative and cosmetic medicine. PRP is also relatively easy to prepare with supplies on hand in most IVF clinics. Specifically relating to reproductive function, PRP has been demonstrated to increase cellular proliferation and decrease fibrosis in damaged rat endometrium. It is hypothesized that infusing the uterus with Platelet Rich Plasma at measured intervals prior to embryo transfer will increase concentrations of implantation-promoting cytokines while reducing concentrations of inflammatory cytokines during the window of implantation.

Who can participate

Age range23 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient at REI clinic population * Ages 23 to 45 * Undergo frozen embryo transfers with clinic standard medicated protocols * Transferring one or two embryos on day 5 or 6 of development Exclusion Criteria: * BMI \>32 * Low level or high-level mosaic * Aneuploid embryos only will be excluded * Desiring day 3 or fresh embryo

What they're measuring

Determine the effect of autologous uterine PRP infusion on factors critical to the implantation process

Timeframe: 18 months

Trial details

NCT IDNCT06621342

SponsorUniversity of Kansas Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-16

View on ClinicalTrials.gov More Infertility trials